Friday, August 27, 2021

QualityStocksNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Closes on $3M Convertible Note

 Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures, announced that it had secured a new convertible note totaling $3 million. Financing for the note, which was comprised of three tranches, was led by Rapha Capital BioVentures Fund I, LP (“RCBVFI”). The company anticipates using the funds  to support the clinical development of its lead product, the i/Blue(TM) Imaging System. According to the company, the proprietary system is poised to increase patient access to this important technology. In addition to the funding, Imagin Medical also named Kevin Slawin, MD, a leading uro oncologist and manager of RCBVFI, as a new board member. Slawin has cared for patients with cancer for more than 25 years and brings with him a deep knowledge of the field and of the needs of patients with prostate and bladder cancer. According to the announcement, Slawin noted that taking the lead investor role in Imagin signifies his appreciation of Imagin’s advanced technology and the potential it may bring to the improvement in the care of these patients. Finally the company also unveiled a new enhanced website, which features its new logo and reflects the change in energy and direction of Imagin Medical. “We are excited to bring Dr. Slawin onto the leadership team as a board member at Imagin Medical,” said Imagin Medical president and CEO Jim Hutchens in the press release. “This additional funding will support the company’s progress in bringing our lead product, the i/Blue(TM) Imaging System, through the FDA submission process over the next year.”

To view the full press release, visit https://ibn.fm/wQ3oH

About Imagin Medical 

Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i/Blue Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The company’s initial focus is bladder cancer. For more information about the company, visit www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

No comments: